Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500354 | 0.90 | MAPK1 (0.59) | MAPTLMNAESR1ESR2PKM | |
| SCHEMBL10500136 | 0.90 | CES2 (0.45) | MAPTLMNAESR1ESR2PKM | |
| SCHEMBL14567121 | 0.89 | CES2 (0.54) | MAPTLMNAESR1ESR2PKM | |
| SCHEMBL14599304 | 0.89 | CES2 (0.54) | MAPTLMNAESR1PKMHPGD | |
| SCHEMBL10499787 | 0.85 | CA2 (0.55) | MAPTESR1ESR2CA1CA2 | |
| SCHEMBL3628183 | 0.85 | CA2 (0.47) | MAPTLMNAESR1ESR2PKM | |
| SCHEMBL10499758 | 0.85 | MAPT (0.50) | MAPTLMNAESR2PKMHTT | |
| SCHEMBL14567124 | 0.84 | CES1 (0.52) | MAPTLMNAHTTCA1CA2 | |
| SCHEMBL3620902 | 0.84 | MEN1 (0.44) | MAPTLMNAHPGDHTTALDH1A1 | |
| SCHEMBL3626361 | 0.83 | TTR (0.47) | MAPTLMNAESR1ESR2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | claimed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | claimed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | claimed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | MAPT 2177/4885LMNA 560/4885ESR1 627/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | MAPT 2177/4885LMNA 560/4885ESR1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.